- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 28.07. | Boehringer eyes $1B deal to use Re-Vana's drug delivery tech on ophthalmic pipeline | ||
| 28.07. | Atai's schizophrenia drug fails to improve cognition in phase 2 study | ||
| 28.07. | Celcuity's breast cancer combo hits primary endpoints, teeing up FDA filing | ||
| 28.07. | GSK strengthens COPD offering via $12B biobucks, 12-program deal with China's Hengrui Pharma | ||
| 25.07. | Chinese antibody developer Leads Biolabs hits Hong Kong stock exchange in $189M IPO | ||
| 25.07. | BMS names AstraZeneca's Cristian Massacesi as new chief medical officer | ||
| 25.07. | 'We will crack gene therapy': Elevidys fallout doesn't dent Roche's hopes for modality | ||
| 25.07. | Memo pushes kidney drug to phase 3 despite primary endpoint miss | ||
| 24.07. | Brandon Capital raises $290M for its largest life sciences fund yet | ||
| 24.07. | Lilly opens Gate to new small molecule drug class with $856M biobucks deal | ||
| 24.07. | Novartis puts $1B on the line to court preclinical biotech Matchpoint | ||
| 24.07. | Galapagos builds island of cell therapies to prep for potential sale amid pipeline pruning | ||
| 24.07. | Cell therapy biotech Adicet turns to autoimmune, shedding a phase 1 asset and 30% of staffers | ||
| 24.07. | Rocket adjusts trajectory, laying off 30% of staff and narrowing pipeline focus | ||
| 24.07. | AstraZeneca's blockbuster contender hits phase 3 goals, fueling myasthenia gravis fight | ||
| 24.07. | Roche axes Carmot obesity asset, 3 cancer drugs in R&D clear-out | ||
| 23.07. | Genentech eliminates 87 jobs in another round of South San Francisco layoffs | ||
| 23.07. | With $550M on the line, Arrowhead reassures investors about pact with troubled Sarepta | ||
| 23.07. | FDA opens national priority fast track, offering 2-month reviews to onshoring and affordability projects | ||
| 22.07. | Scancell picks winner from phase 2 cancer vaccine face-off, choosing next-gen prospect for pivotal trial | ||
| 22.07. | Replimune's shares crater as FDA rejects melanoma drug | ||
| 22.07. | Sanofi tightens grip on RSV, paying $1.15B upfront for Vicebio, boosting its pipeline beyond mRNA | ||
| 21.07. | Sarepta LGMD trials all hit by FDA hold amid newly surfaced safety concerns over gene therapy | ||
| 21.07. | iTeos, reeling from TIGT fail, becomes latest prize for deal-hungry Concentra | ||
| 21.07. | Alkermes reports phase 2 narcolepsy win, advancing challenge to Takeda's blockbuster dream |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .